ClinicalTrials.gg
RecruitingNCT06271265Updated Dec 29, 2025

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

A Phase 1 interventional study of EXPAREL and bupivacaine in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Recruiting at 5 sites in United States. Open to participants aged 0 Years to 6 Years. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
0 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.

Planned enrollment
68th of 93
48 · median 80
Started
2024
with 8 others
Phase 1
8 of 93
2 open now
Primary completion
2027-01
later than 6 of 14 live
Registered
81st of 93
by date
Lead sponsor
11 of 93
Pacira Pharmaceuticals, Inc

Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 68th largest by planned enrollment, is one of 9 that started in 2024, is one of 8 in phase 1, reaches primary completion later than 6 of the 14 other live ones, and was the 81st registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 0 Years to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA).

Read the detailed description

This study will be conducted in 3 Parts (Part 1, Part 2, and Part 3) and a total of approximately 48 male and female subjects will be enrolled.

Part 1 will enroll approximately 16 subjects, aged 2 to less than 6 years to obtain information on PK and safety. Subjects will be randomized 1:1 (8 EXPAREL subjects and 8 bupivacaine HCl subjects) to receive either a single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) or 0.25% bupivacaine HCl 2 mg/kg (not to exceed a maximum total dose of 175 mg) using LIA. The overall PK and safety profiles from Part 1 will be completed, analyzed, and reviewed to establish an appropriate study drug dose for Part 2.

Subject enrollment for Part 2 will commence upon complete enrollment of Part 1, establishment of an appropriate study drug dose from the PK, and safety analysis of Part 1 and Data Safety Monitoring Board (DSMB) recommendations to proceed to Part 2. Part 2 will enroll approximately 16 subjects, aged 6 months to less than 2 years to obtain information on PK and safety. Subjects will be randomized 1:1 (8 EXPAREL subjects and 8 bupivacaine HCl subjects) to receive either a single dose of EXPAREL or 0.25% bupivacaine HCl using LIA. The overall PK and safety profiles from Part 2 will be completed, analyzed, and reviewed to establish an appropriate study drug dose for Part 3.

Subject enrollment for Part 3 will commence upon complete enrollment of Part 2, establishment of an appropriate study drug dose from the PK and safety analysis of Part 2, and DSMB recommendations to proceed to Part 3.

Part 3 will enroll approximately 16 subjects aged 0 to less than 6 months to obtain information on PK and safety. Subjects will be randomized 1:1 (8 EXPAREL subjects and 8 bupivacaine HCL subjects) to receive either a single dose of EXPAREL or 0.25% bupivacaine HCl using LIA.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • Analgesia
  • Cardiac Surgery
  • Pediatric
04

Who can participate

Ages eligible
0 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

All of the following inclusion criteria must be met for eligibility:

  1. Pediatric participants with congenital heart defects planned to undergo cardiac surgery with cardiopulmonary bypass
  2. Male or female participants from 0 to less than 6 years of age on the day of surgery: 2 years to less than 6 years of age for Part 1; 6 months to less than 2 years of age for Part 2; 0 to less than 6 months of age for Part 3
  3. (ASA) Classes 1 through 4.
  4. Parent/guardian is able to speak, read, and understand the language of the ICF and provide for the participant.
  5. Parent/guardian is able to adhere to the study visit schedule and complete all study assessments for the participant.

Exclusion Criteria:

Exclusion Criteria:

A participant will not be eligible for the study if any of the following exclusion criteria are met:

  1. History of or idiosyncratic reactions or contradictions to EXPAREL, bupivacaine HCl, or other amide-type local anesthetics or to opioid medications
  2. Administration of EXPAREL or bupivacaine HCl within 30 days prior to IP administration
  3. Administration of an IP within 30 days or 5 elimination half-lives of such IP, whichever is longer, prior to IP administration, or planned administration of another IP or procedure during participation in this study
  4. History of preterm birth (before 35 weeks of pregnancy)
  5. History of coagulopathies or immunodeficiency disorders
  6. Disease or condition that, in the opinion of the Investigator, indicates an increased vulnerability to IPs and/or procedures
  7. Recent or potential exposure to COVID-19
  8. Cardiac surgery has been canceled and cannot be rescheduled within 30 days of signing the ICF because of any reason.
  9. Necessity in delayed wound closure
  10. Informed consent withdrawn before randomization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    EXPAREL

    A total of approximately 24 subjects (8 subjects per Part) will be enrolled. Subjects in this arm will receive EXPAREL

    Drug: EXPAREL

  • Active comparator
    bupivacaine

    A total of approximately 24 subjects (8 subjects per Part) will be enrolled. Subjects in this arm will receive bupivacaine

    Drug: bupivacaine

Interventions

  • A single dose of EXPAREL Injectable Product via LIA

  • A single dose of 0.25% bupivacaine via LIA

06

What researchers measure

Primary outcomes

  1. The following model-predicted PK endpoint will be determined:

    • Area under the plasma concentration-versus-time curve (AUClast and AUC0-inf)

    Time frame: through 72 hours

  2. The following model-predicted PK endpoint will be determined:

    • Maximum observed plasma concentration (Cmax)

    Time frame: through 72 hours

  3. The following model-predicted PK endpoint will be determined:

    • Time of maximum observed plasma concentration (Tmax)

    Time frame: through 72 hours

  4. The following model-predicted PK endpoint will be determined:

    • The apparent terminal elimination half-life (t1/2)

    Time frame: through 72 hours

  5. The following model-predicted PK endpoint will be determined:

    • Apparent clearance (CL)

    Time frame: through 72 hours

  6. The following model-predicted PK endpoint will be determined:

    • Apparent volume of distribution (Vd)

    Time frame: through 72 hours

Secondary outcomes

  1. Vitals change from Baseline:

    temperature

    Time frame: up to 4 postoperative days

  2. Vitals change from Baseline:

    heart rate

    Time frame: up to 4 postoperative days

  3. Vitals change from Baseline:

    respiratory rate

    Time frame: up to 4 postoperative days

  4. Vitals change from Baseline:

    oxygen saturation

    Time frame: up to 4 postoperative days

  5. Vitals change from Baseline:

    blood pressure

    Time frame: up to 4 postoperative days

  6. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: 14 ± 3 days

  7. Incidence of adverse events of special interest (AESIs)

    Time frame: 14 ± 3 days

  8. Incidence of serious adverse events (SAEs)

    Time frame: 14 ± 3 days

07

Study locations

5 of 5 sites recruiting
  • Indiana University Health, Riley Hospital For Children
    Indianapolis, Indiana 46202, United States
    Recruiting
  • St. Louis Children's Hospital (SLCH)
    St Louis, Missouri 63110, United States
    Recruiting
  • Duke University Health System
    Durham, North Carolina 27710, United States
    Recruiting
  • University of Oklahoma (OU) - Medical Center - The Children's Hospital
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • The University of Texas Health Science Center at Houston (UTHSC-H) - McGovern Medical School
    Houston, Texas 77030, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jan 2027, 34 months after the start.

Of 83 phase 1 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2024
First posted
Feb 21, 2024
StartActual
Mar 29, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06271265
Responsible party
Sponsor
First posted
Feb 21, 2024
Start date
Mar 29, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Dec 29, 2025

Study contacts

Sarah Shaffer
Contact
sarah.shaffer@pacira.com
973-451-4071

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion